NCT06367088View on ClinicalTrials.gov

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions

Triple-negative Breast CancerCadonilimab

Interventions

DRUG

Cadonilimab

Patients were assigned to receive 10 mg/kg cadonilimab intravenously Q3W in combination with chemotherapy. The chemotherapy regimen is chosen by the physician.

Trial Locations (1)

430022

RECRUITING

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER